Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD Trials

Affiliations

• ¹ Division of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, California; Department of Pediatrics, Division of Pediatric Nephrology, University of California, San Francisco, San Francisco, California; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. Electronic address: elaine.ku@ucsf.edu.
• ² Division of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, California.
• ³ Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
• ⁴ Center for Biostatistics & Qualitative Methodology, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
• ⁵ Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
• ⁶ Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts.
• ⁷ Division of Nephrology, Department of Medicine, Emory University, Atlanta, Georgia.
• ⁸ Division of Nephrology, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas.
• ⁹ School of Medicine, Harvard University, Boston, Massachusetts.
• ¹⁰ Department of Medicine, Division of Nephrology, University of Chicago, Chicago, Illinois.